Fitch Affirms Ratings on Pfizer (PFE) Amid Decision to Remain Whole
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East uncertainty lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Wall Street ends down as oil prices, Treasury yields rise
Moody's Affirms Pfizer's (PFE) Ratings Amid Decision Not to Split Company
September 26, 2016 2:12 PM EDTMoody's Investors Service ("Moody's") affirmed the ratings of Pfizer Inc. (NYSE: PFE) and related subsidiaries, including the A1 senior unsecured long-term rating and the Prime-1 commercial paper rating. At the same time, Moody's revised the rating outlook to stable from negative. This rating action follows the announcement that Pfizer will not pursue a split of its pharmaceutical business.
"Pfizer's decision to keep the business whole removes a key overhang to the credit profile because a split had credit negative implications," stated Michael Levesque, Moody's Senior Vice President.
"The stable rating outlook... More
Pfizer decides against split-up; more deals seen likely
September 26, 2016 7:18 AM EDTBy Ransdell Pierson and Bill Berkrot
NEW YORK (Reuters) - Pfizer Inc (NYSE: PFE), which was considering splitting itself for more than two years, said on Monday it would not do so, prompting shareholders to expect more deals that could bolster its roster of new medicines.
The largest U.S. drugmaker said its lengthy analysis determined that splitting off its low-growth generics from its patent-protected branded products would not boost cash flow or better position the businesses competitively. The move would also disrupt operations, have inherent costs and fail to deliver any tax... More
Pfizer (PFE) Won't Pursue Split
September 26, 2016 6:47 AM EDTPfizer Inc. (NYSE: PFE) announced that, after an extensive evaluation, the companys Board of Directors and Executive Leadership Team have determined the company is best positioned to maximize future shareholder value creation in its current structure and will not pursue splitting Pfizer Innovative Health and Pfizer Essential Health into two, separate publicly traded companies at this time.
With this decision, our two distinct businesses will remain separately managed units within Pfizer, which we believe is currently the best structure to continue to deliver on our commitments to patients, physicians, payers and... More
